Once versus multiple daily dosing of aminoglycosides for patients with febrile neutropenia: A systematic review and meta-analysis

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 2, 2011, Pages 251-259

  Mavros, Michael N ^a   Polyzos, Konstantinos A ^a   Rafailidis, Petros I ^a,b   Falagas, Matthew E ^a,b,c  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b HENRY DUNANT HOSPITAL   (Greece)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Amikacin; Netilmicin; Neutropenic fever; Once daily; Single daily; Tobramycin

Indexed keywords

AMIKACIN; AZLOCILLIN; CARBENICILLIN; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; NETILMICIN; PENICILLIN G; PIPERACILLIN; TOBRAMYCIN;

ARTICLE; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; HUMAN; META ANALYSIS (TOPIC); MORTALITY; NEPHROTOXICITY; OTOTOXICITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW;

AMINOGLYCOSIDES; DRUG ADMINISTRATION SCHEDULE; FEVER; HUMANS; NEUTROPENIA; TREATMENT OUTCOME;

EID: 78651449264     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq451     Document Type: Article

References (48)

1. Leibovici L, Vidal L, Paul M. Aminoglycoside drugs in clinical practice: an evidence-based approach. J Antimicrob Chemother 2009; 63: 246-51.
2. Durante-Mangoni E, Grammatikos A, Utili R et al. Do we still need the aminoglycosides? Int J Antimicrob Agents 2009; 33: 201-5.
3. Ali MZ, Goetz MB. A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997; 24: 796-809.
4. Bailey TC, Little JR, Littenberg B et al. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997; 24: 786-95.
5. Barza M, Ioannidis JP, Cappelleri JC et al. Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ 1996; 312: 338-45.
6. Contopoulos-Ioannidis DG, Giotis ND, Baliatsa DV et al. Extended-interval aminoglycoside administration for children: a meta-analysis. Pediatrics 2004; 114: e111-8.
7. Ferriols-Lisart R, Alos-Alminana M. Effectiveness and safety of once-daily aminoglycosides: a meta-analysis. Am J Health Syst Pharm 1996; 53: 1141-50.
8. Freeman CD, Strayer AH. Mega-analysis of meta-analysis: an examination of meta-analysis with an emphasis on once-daily aminoglycoside comparative trials. Pharmacotherapy 1996; 16: 1093-102.
9. Galloe AM, Graudal N, Christensen HR et al. Aminoglycosides: single or multiple daily dosing? A meta-analysis on efficacy and safety. Eur J Clin Pharmacol 1995; 48: 39-43.
10. Hatala R, Dinh T, Cook DJ. Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. Ann Intern Med 1996; 124: 717-25.
11. Hatala R, Dinh TT, Cook DJ. Single daily dosing of aminoglycosides in immunocompromised adults: a systematic review. Clin Infect Dis 1997; 24: 810-5.
12. Munckhof WJ, Grayson ML, Turnidge JD. A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrob Chemother 1996; 37: 645-63.
13. Aiken SK, Wetzstein GA. Once-daily aminoglycosides in patients with neutropenic fever. Cancer Control 2002; 9: 426-31.
14. Hughes WT, Armstrong D, Bodey GP et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730-51.
15. Furno P, Bucaneve G, Del Favero A. Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis. Lancet Infect Dis 2002; 2: 231-42.
16. de Naurois J, Novitzky-Basso I, Gill MJ et al. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol 2010; 21 Suppl 5: v252-6.
17. Rosmarakis ES, Soteriades ES, Vergidis PI et al. From conference abstract to full paper: differences between data presented in conferences and journals. FASEB J 2005; 19: 673-80.
18. Moher D, Pham B, Jones A et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998; 352: 609-13.
19. Viscoli C, Bruzzi P, Glauser M. An approach to the design and implementation of clinical trials of empirical antibiotic therapy in febrile and neutropenic cancer patients. Eur J Cancer 1995; 31: 2013-22.
20. Egger M, Davey Smith G, Schneider M et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34.
21. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.
22. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-48.
23. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 1993; 119: 584-93.
24. Ariffin H, Arasu A, Mahfuzah M et al. Single-daily ceftriaxone plus amikacin versus thrice-daily ceftazidime plus amikacin as empirical treatment of febrile neutropenia in children with cancer. J Paediatr Child Health 2001; 37: 38-43.
25. Charnas R, Luthi AR, Ruch W, Writing Committee for the International Collaboration on Antimicrobial Treatment of Febrile Neutropenia in Children. Once daily ceftriaxone plus amikacin vs. three times daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancer. Pediatr Infect Dis J 1997; 16: 346-53.
26. Hansen M, Achen F, Carstensen C et al. Once-versus thrice-daily dosing of netilmicin in febrile immunocompromised patients: a randomized, controlled study of efficacy and safety. J Drug Dev 1988; 1: 119-24.
27. Kiel PJ, Lo M, Stockwell D et al. An evaluation of amikacin nephrotoxicity in the hematology/oncology population. Am J Ther 2008; 15: 131-6.
28. Rozdzinski E, Kern WV, Reichle A et al. Once-daily versus thrice-daily dosing of netilmicin in combination with β-lactam antibiotics as empirical therapy for febrile neutropenic patients. J Antimicrob Chemother 1993; 31: 585-98.
29. Solorzano-Santos F, Miranda-Novales MG, Diaz-Pena R et al. [Amikacin in single daily doses in children with fever]. Rev Invest Clin 1996; 48:13-8.
30. Sung L, Dupuis LL, Bliss B et al. Randomized controlled trial of once-versus thrice-daily tobramycin in febrile neutropenic children undergoing stem cell transplantation. J Natl Cancer Inst 2003; 95: 1869-77.
31. Torfoss D, Hoiby EA, Tangen JM et al. Tobramycin once versus three times daily, given with penicillin G, to febrile neutropenic cancer patients in Norway: a prospective, randomized, multicentre trial. J Antimicrob Chemother 2007; 59: 711-7.
32. MacArthur RD, Lolans V, Zar FA et al. Biphasic, concentration-dependent and rate-limited, concentration-independent bacterial killing by an aminoglycoside antibiotic. J Infect Dis 1984; 150: 778-9.
33. Moore RD, Smith CR, Lietman PS. Association of aminoglycoside plasma levels with therapeutic outcome in Gram-negative pneumonia. Am J Med 1984; 77: 657-62.
34. Moore RD, Smith CR, Lietman PS. The association of aminoglycoside plasma levels with mortality in patients with Gram-negative bacteremia. J Infect Dis 1984; 149: 443-8.
35. Craig WA. Post-antibiotic effects in experimental infection models: relationship to in-vitro phenomena and to treatment of infections in man. J Antimicrob Chemother 1993; 31 Suppl D: 149-58.
36. Spivey JM. The postantibiotic effect. Clin Pharm 1992; 11: 865-75.
37. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155:93-9.
38. Daikos GL, Lolans VT, Jackson GG. First-exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use. Antimicrob Agents Chemother 1991; 35: 117-23.
39. Nicolau DP, Freeman CD, Belliveau PP et al. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother 1995; 39: 650-5.
40. Rougier F, Claude D, Maurin M et al. Aminoglycoside nephrotoxicity: modeling, simulation, and control. Antimicrob Agents Chemother 2003; 47: 1010-6.
41. Verpooten GA, Giuliano RA, Verbist L et al. Once-daily dosing decreases renal accumulation of gentamicin and netilmicin. Clin Pharmacol Ther 1989; 45:22-7.
42. Nicolau DP, Wu AH, Finocchiaro S et al. Once-daily aminoglycoside dosing: impact on requests and costs for therapeutic drug monitoring. Ther Drug Monit 1996; 18: 263-6.
43. Kumana CR, Yuen KY. Parenteral aminoglycoside therapy. Selection, administration and monitoring. Drugs 1994; 47: 902-13.
44. Fantin B, Ebert S, Leggett J et al. Factors affecting duration of in-vivo postantibiotic effect for aminoglycosides against Gram-negative bacilli. J Antimicrob Chemother 1991; 27: 829-36.
45. Kapusnik JE, Hackbarth CJ, Chambers HF et al. Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental pseudomonas pneumonia. J Infect Dis 1988; 158: 7-12.
46. McDonald PJ, Wetherall BL, Pruul H. Postantibiotic leukocyte enhancement: increased susceptibility of bacteria pretreated with antibiotics to activity of leukocytes. Rev Infect Dis 1981; 3: 38-44.
47. Gerber AU, Kozak S, Segessenmann C et al. Once-daily versus thrice-daily administration of netilmicin in combination therapy of Pseudomonas aeruginosa infection in a man-adapted neutropenic animal model. Eur J Clin Microbiol Infect Dis 1989; 8: 233-7.
48. Falagas ME, Vardakas KZ, Samonis G. Decreasing the incidence and impact of infections in neutropenic patients: evidence from meta-analyses of randomized controlled trials. Curr Med Res Opin 2008; 24: 215-35.